ArticleArchives of medical science : AMS2026
Exosomes derived from bone marrow mesenchymal stem cells pre-treated with curcumin alleviate osteoporosis by promoting osteogenic differentiation via regulating the METTL3/microRNA-320/RUNX2 signaling pathway.
Article in Archives of medical science : AMS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Curcumin (CUR) has been reported to stimulate the expression of methyltransferase-like 3 (METTL3), a potential therapeutic target for osteoporosis. Also, bone marrow mesenchymal stem cell (BMSC)-derived exosomes (EXO) have been demonstrated to improve osteoporosis by pro-moting the proliferation of osteoblasts. In this study, we aimed to study the effect of CUR and BMSC-derived exosomes in the treatment of osteoporosis. Material and methods: Microscopy was used to characterize exosomes derived from BMSCs. MicroCT was carried out to analyze the parameters of bone formation. Western blot was carried out to analyze the expression of surface markers on BMSC-derived exosomes and METTL3/Runt-related transcription factor 2 (RUNX2) proteins under different conditions. Realtime PCR was used to assess the gene expression under different circumstances. Results: The exosomes derived from CUR-treated BMSCs showed an enhanced therapeutic effect on osteoporotic mice compared with exosomes derived from untreated BMSCs. Mechanistically, CUR pretreatment of BMMSCs significantly enhanced the ability of BM-MSCderived exosomes to restore the dysregulated expression of METTL3, miR-320, and RUNX2. Addi-tionally, CUR treatment of BMSCs markedly enhanced the stimulatory effect of BMSC-derived exosomes on the expression of METTL3, miR-320, RUNX2, BGLAP, and LAP in BMSCs. Furthermore, luciferase assay demonstrated that miR-320 was capable of suppressing the expression of RUNX2 through binding to the 3' UTR of RUNX2. Conclusions: Our study demonstrated that BMSC-derived exosomes could modulate the METTL3/miRNA-320/RUNX2 axis to attenuate osteoporosis by promoting osteogenic differentiation of BMSCs. Moreover, the CUR treatment of BMSCs promoted the therapeutic effect of BMSC-derived exosomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.